Table 2 The pooled results of association between clinical prognosis and MIR31HG expression
Outcomes | Studies | Participants | HRs and 95% CIs | Model | Heterogeneity |
|---|---|---|---|---|---|
P, I2 | |||||
OS | |||||
 Total | 11 | 1096 | 1.10 (0.60, 2.03) | Random | < 0.001, 88.1% |
 Gastrointestinal cancer | 5 | 604 | 0.56 (0.41, 0.77) | Random | 0.825, 0% |
 Lung cancer | 3 | 270 | 1.64 (1.15, 2.34) | Random | 0.615, 0% |
 Other cancers | 3 | 222 | 3.37 (2.69, 4.23) | Random | 0.746, 0% |
DFS | 2 | 335 | 0.44 (0.27, 0.72) | Fixed | 0.551, 0% |
RFS | 3 | 1367 | 2.54 (1.91, 3.38) | Fixed | 0.610, 0% |